Impact of TLR4 Gene Variants on Head and Neck Cancer Outcomes
Author Information
Author(s): Bergmann Christoph, Bachmann Hagen S, Bankfalvi Agnes, Lotfi Ramin, Pütter Carolin, Wild Clarissa A, Schuler Patrick J, Greve Jens, Hoffmann Thomas K, Lang Stephan, Scherag André, Lehnerdt Götz F
Primary Institution: University of Duisburg - Essen
Hypothesis
The study investigates the impact of TLR4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile on the clinical outcomes of head and neck squamous cell carcinomas (HNSCC).
Conclusion
TLR4 299Gly and 399Ile alleles may serve as markers for prognosis in head and neck cancer patients undergoing adjuvant systemic therapy.
Supporting Evidence
- Patients with the TLR4 Asp299Gly genotype had significantly reduced disease-free and overall survival.
- Adjuvant systemic therapy was associated with poorer therapy response in patients carrying the Asp299Gly variant.
- Significant associations were found between TLR4 genotypes and disease advancement.
Takeaway
This study found that certain gene changes in patients with head and neck cancer can help predict how well they will respond to treatment.
Methodology
Genotype analysis was performed on DNA from tissue samples of 188 HNSCC patients, and TLR4 protein expression was assessed using immunohistochemistry.
Potential Biases
There may be risks of bias due to the retrospective nature of the study and the reliance on existing patient data.
Limitations
The study has limitations due to the small sample size and potential biases in patient selection.
Participant Demographics
The cohort consisted of 188 patients with head and neck squamous cell carcinomas, with a median follow-up of 50 months.
Statistical Information
P-Value
0.04
Confidence Interval
95%CI: 1.01-4.06
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website